Abiraterone Acetate Versions for Treatment of mCRPC

This video segment explores how to choose between the original brand, generic, and micronized versions of abiraterone, considering factors like efficacy, cost, patient preference, and clinical context.

EP: 1.Bone Predominant mCRPC Patient Case

EP: 2.Case 1: A 68-Year-Old Man with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Now Viewing

EP: 3.Abiraterone Acetate Versions for Treatment of mCRPC

EP: 4.Patient Selection Criteria for Different Versions of Abiraterone Acetate in mCRPC

EP: 5.Assessing Treatment Efficacy: Communication with Patients and Caregivers

EP: 6.Patient with mCRPC and Hepatic Disease

EP: 7.Treatment and Co-Management of mCRPC Patients with Aggressive Disease

Video content above is prompted by the following:

• Abiraterone is now available as the original brand, generic and micronized versions. How do you choose between these different options of abiraterone?

Related Videos